NCT00417118 - An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder | Biotech Hunter

Enrollment

365

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Generalized Anxiety

Interventions

DRUG

Saredutant

oral administration (capsules)

DRUG

Escitalopram

oral administration (capsules)

DRUG

Placebo

oral administration (capsules)

Trial Locations (7)

Sanofi-Aventis Administrative Office, Brussels

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Stockholm

Sanofi-Aventis Administrative Office, Istanbul